Back to Journals » Drug Design, Development and Therapy » Volume 13

Original Research

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

       
Total article views   HTML views PDF downloads Totals
11,494 Dovepress* 9,810+ 1,264 11,074
PubMed Central* 1,684 380 2,064
Totals 11,494 1,644 13,138
*Since 29 March 2019
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 1 3

View citations on PubMed Central and Google Scholar